Search

Your search keyword '"Bouguen G"' showing total 395 results
Start Over Author "Bouguen G"
395 results on '"Bouguen G"'

1. AB1493 PATIENT SATISFACTION AND EXPERIENCE AFTER A SWITCH TO AN ADALIMUMAB BIOSIMILAR WITH HIGH CONCENTRATION AND CITRATE-FREE: RESULTS FROM A MULTICENTRIC PROSPECTIVE REAL-LIFE STUDY

Author

Marotte, H., primary, Gossec, L., additional, Abitbol, V., additional, Senbel, E., additional, Bonnaud, G., additional, Roblin, X., additional, Bouhnik, Y., additional, Nancey, S., additional, Mathieu, N., additional, Filippi, J., additional, Vuitton, L., additional, Nahon, S., additional, Dellal, A., additional, Denis, A., additional, Habauzit, C., additional, Benkhalifa, S., additional, and Bouguen, G., additional

Published
2024
Full Text
View/download PDF

3. P386 Persistence of bowel urgency despite clinical remission after induction therapy is associated with unfavorable long-term outcomes in patients with ulcerative colitis: results from the multicenter UC-RGENCY study

Author

Buisson, A, primary, Amiot, A, additional, Nachury, M, additional, Altwegg, R, additional, Serrero, M, additional, Guilmoteau, T, additional, Treton, X, additional, Caillo, L, additional, Vuitton, L, additional, Bouguen, G, additional, Pereira, B, additional, and Fumery, M, additional

Published
2024
Full Text
View/download PDF

4. P884 Patient satisfaction and experience after a switch to an adalimumab biosimilar with high concentration and citrate-free: results from a multicentric prospective real-life study

Author

Bouguen, G, primary, Gossec, L, additional, Abitbol, V, additional, Senbel, E, additional, Bonnaud, G, additional, Roblin, X, additional, Bouhnik, Y, additional, Nancey, S, additional, Mathieu, N, additional, Filippi, J, additional, Vuitton, L, additional, Nahon, S, additional, Dellal, A, additional, Denis, A, additional, Habauzit, C, additional, Benkhalifa, S, additional, and Marotte, H, additional

Published
2024
Full Text
View/download PDF

5. P322 Compared Efficacy of Second-Line Treatments for Ulcerative Colitis After Failure of Vedolizumab in First-Line Treatment: A Retrospective Multicenter Study

Author

Calmejane, L, primary, Reenaers, C, additional, Amiot, A, additional, Nuzzo, A, additional, Vuitton, L, additional, Altwegg, R, additional, Guillo, L, additional, Wils, P, additional, Roblin, X, additional, Le Cosquer, G, additional, Simon, M, additional, Benezech, A, additional, Laharie, D, additional, Fumery, M, additional, Buisson, A, additional, Charkaoui, M, additional, Nancey, S, additional, Sabra, G, additional, Geyl, S, additional, Coffin, B, additional, Cavicchi, M, additional, Le Berre, C, additional, Goutorbe, F, additional, Bouguen, G, additional, Vidon, M, additional, Christmann, P Y, additional, Kirchgesner, J, additional, and Uzzan, M, additional

Published
2024
Full Text
View/download PDF

6. DOP65 Infliximab plus azathioprine and quick steroids discontinuation versus azathioprine plus steroids in patients with acute severe Ulcerative Colitis responding to intravenous steroids: a parallel, open-label randomized controlled trial

Author

Amiot, A, primary, Seksik, P, additional, Meyer, A, additional, Stefanescu, C, additional, Wils, P, additional, Altwegg, R, additional, Vuitton, L, additional, Plastaras, L, additional, Nicolau, A, additional, Buisson, A, additional, Duveau, N, additional, Laharie, D, additional, Boualit, M, additional, Allez, M, additional, Coffin, B, additional, Chanteloup, E, additional, Bouguen, G, additional, Vicaut, E, additional, and Peyrin-Biroulet, L, additional

Published
2024
Full Text
View/download PDF

7. P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial

Author

Vuitton, L, primary, Poullenot, F, additional, Bouhnik, Y, additional, Wils, P, additional, Buisson, A, additional, Viennot, S, additional, Bouguen, G, additional, Hébuterne, X, additional, Gilletta, C, additional, Nancey, S, additional, Bourreille, A, additional, Amil, M, additional, Altwegg, R, additional, Goutorbe, F, additional, Caillo, L, additional, Plastaras, L, additional, Brixi, H, additional, Simon, M, additional, Serrero, M, additional, Fumery, M, additional, Rahier, J F, additional, Vicaut, E, additional, and Peyrin-Biroulet, L, additional

Published
2024
Full Text
View/download PDF

8. P903 Persistence, efficacy and tolerance of subcutaneous Infliximab after switch from intravenous infliximab in IBD patients in remission: one-year results from a multicenter prospective cohort

Author

Mathieu, N, primary, Heluwaert, F, additional, Riviere, P, additional, Hebuterne, X, additional, Chupin, A, additional, Abitbol, V, additional, Bouguen, G, additional, Vuitton, L, additional, Allez, M, additional, Montuclard, C, additional, Nancey, S, additional, Biron, A, additional, Wils, P, additional, Gilletta, C, additional, De Maissin, A, additional, Altwegg, R, additional, Chanteloup, E, additional, Plastaras, L, additional, Ah-Soune, P, additional, Bourreille, A, additional, Bouhnik, Y, additional, Seksik, P, additional, Simon, M, additional, Uzzan, M, additional, Andrau, P, additional, Rouillon, C, additional, Arondel, Y, additional, Peyrin-Biroulet, L, additional, Laharie, D, additional, Vicaut, E, additional, and Hupe, M, additional

Published
2024
Full Text
View/download PDF

10. AB1826-HPR HOW TO ASSESS THE SATISFACTION OF PATIENTS WITH CHRONIC INFLAMMATORY DISEASES AFTER SWITCHING TO A BIOSIMILAR? INSIGHTS FROM AN EXPLORATORY QUALITATIVE STUDY PRELIMINARY TO AN OBSERVATIONAL STUDY

Author

Bouguen, G., primary, Peyrin-Biroulet, L., additional, Buisson, A., additional, Lafarge, D., additional, Tropé, S., additional, Montagu, G., additional, Denis, A., additional, Habauzit, C., additional, Benkhalifa, S., additional, and Marotte, H., additional

Published
2023
Full Text
View/download PDF

11. P320 Confocal Laser Endomicroscopy to predict the efficacy of vedolizumab as first-line biotherapy in ulcerative colitis

Author

Quénéhervé, L, primary, Trang-Poisson, C, additional, Fantou, A, additional, Flamant, M, additional, Durand, T, additional, Bouguen, G, additional, Bregeon, J, additional, Oullier, T, additional, Amil, M, additional, Dewitte, M, additional, Bardot, S, additional, Braudeau, C, additional, Josien, R, additional, Neunlist, M, additional, and Bourreille, A, additional

Published
2023
Full Text
View/download PDF

12. P404 Persistence of subcutaneous infliximab after switching from intravenous in a French national cohort of IBD patients in remission

Author

Mathieu, N, primary, Riviere, P, additional, Heluwaert, F, additional, Hébuterne, X, additional, Chupin, A, additional, Bouguen, G, additional, Vuitton, L, additional, Allez, M, additional, Montuclard, C, additional, Nachury, M, additional, Nancey, S, additional, Amélie, B, additional, Gilletta, C, additional, Abitbol, V, additional, Altwegg, R, additional, de Maissin, A, additional, Plastaras, L, additional, Ah Soune, P, additional, Boureille, A, additional, Bouhnik, Y, additional, Seksik, P, additional, Chanteloup, E, additional, marion, S, additional, Uzzan, M, additional, Andrau, P, additional, Rouillon, C, additional, Arondel, Y, additional, Peyrin Biroulet, L, additional, and Laharie, D, additional

Published
2023
Full Text
View/download PDF

13. P579 Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study

Author

Buisson, A, primary, Serrero, M, additional, Altwegg, R, additional, Guilmoteau, T, additional, Bouguen, G, additional, Nachury, M, additional, Amiot, A, additional, Vuitton, L, additional, Treton, X, additional, Caillo, L, additional, Pereira, B, additional, and Fumery, M, additional

Published
2023
Full Text
View/download PDF

16. DOP89 Impact of biologics on the risk of early postoperative complications in Crohn's disease: a French nationwide study

Author

Fumery, Mathurin, Nancey, S, Nachury, M, Allez, M, Rouillon, C, Boureille, A, Altwegg, R, Serrero, M, Vuitton, L, Bouguen, G, Abitbol, V, Boualit, M, Biron, A, Panis, Y, Laharie, D, Amiot, A, Simon, M, Caillo, L, Hébuterne, X, Vidon, M, Benezech, A, Elgharabawy, Y, Peyrin-Biroulet, L, CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Claude Huriez [Lille], CHU Lille, Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut de Chimie de Clermont-Ferrand (ICCF), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-SIGMA Clermont (SIGMA Clermont)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Technocentre Renault [Saint-Quentin-en-Yvelines], RENAULT, CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Marseille, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Pontchaillou [Rennes], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre hospitalier [Valenciennes, Nord], CHU Bordeaux [Bordeaux], Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Département de Gastroentérologie, and Hôpital de l'Archet 2

Subjects
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Background While the effect of anti-TNFs on postoperative outcomes in patients with Crohn's disease (CD) has been widely studied, the impact of vedolizumab and ustekinumab on the risk of postoperative complications remains poorly known. Methods All consecutive patients who underwent intestinal resection for CD between July 2014 and April 2022 within 22 French centers were included in a retrospective cohort. The risk of early post-operative complications (≤30days) in patients exposed to biologics was compared to patients not exposed by logistic regression and propensity score-matched analysis adjusted for age, previous intestinal resection, corticosteroids or immunosuppressants exposure, disease activity, presence of abscess, urgent surgery and initial stoma (preoperative contra-indication to anastomosis). Results Among the 1201 patients included, respectively 491 (41%), 76 (6.3%) and 57 (4.7%) were exposed to anti-TNFs, ustekinumab, or vedolizumab within six months before surgery. A total of 317 (26.4%) patients had at least one complication of which 123 (38%) were considered as severe (DINDO III/IV). New surgery was necessary in 69 (5.7%) patients and secondary stoma in 23 (1.9%). Three deaths were observed (0.25%). The rates of overall complications in patients not exposed to biologics, exposed to anti-TNFs, ustekinumab or vedolizumab were respectively 26.1%, 25.1%, 34.7% and 29.8%. The risks of intra-abdominal infectious complications in these four groups were respectively 13.5%, 11.1%, 13.3% and 8.8%. In multivariate analysis, age [OR, 1.02 (1.01-1.04); p=0.004], disease activity [OR, 8.36 (1.79 – 149); p=0.037], the presence of an abscess [OR, 2.01 (1.25-3.20); p=0.004] and initial stoma [OR, 1.70 (1.10 –2.61); p=0.016] were significantly associated with intra-abdominal infectious complications. Conversely, preoperative enteral nutrition [OR, 0.12 (0.01 -0.59); p=0.040] was associated with a reduction in this risk. Exposure to anti-TNFs [OR, 0.80 (0.51-1.24); p=0.31], ustekinumab [OR, 1.17 (0.39-3.51); p=0.78] and vedolizumab [OR, 1.28 (0.32-5.17); p=0.72] within the 3 months before surgery were not associated with the risk of intra-abdominal infectious complications. Similar results were observed in patients exposed to these treatments in the month before surgery. Conclusion In this large cohort, a quarter of patients operated on for CD presented an early postoperative complication and 10% a severe complication. Preoperative exposure to anti-TNFs, vedolizumab or ustekinumab was not associated with an increased risk of early postoperative complications. Preoperative enteral nutrition was associated with a reduced risk of intra-abdominal infectious complication.

Published
2023
Full Text
View/download PDF

19. Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort

Author

Tadbiri, S., Peyrin‐Biroulet, L., Serrero, M., Filippi, J., Pariente, B., Roblin, X., Buisson, A., Stefanescu, C., Trang‐Poisson, C., Altwegg, R., Marteau, P., Vaysse, T., Bourrier, A., Nancey, S., Laharie, D., Allez, M., Savoye, G., Gilletta, C., Gagniere, C., Vuitton, L., Viennot, S., Aubourg, A., Pelletier, A.‐L., Bouguen, G., Abitbol, V., Fumery, M., Claudepierre, P., Bouhnik, Y., Amiot, A., Amiot, Aurelien, Gagniere, Charlotte, Serrero, Melanie, Grimaud, Jean‐Charles, Peyrin‐Biroulet, Laurent, Zallot, Camille, Bigard, Marc‐Andre, Filippi, Jerome, Hebuterne, Xavier, Pariente, Benjamin, Nachury, Maria, Desreumaux, Pierre, Roblin, Xavier, Del Tedesco, Emilie, Buisson, Anthony, Bommelaer, Gilles, Stefanescu, Carmen, Bouhnik, Yoram, Boureille, Arnaud, Trang‐Poisson, Caroline, Altwegg, Romain, Marteau, Philippe, Dray, Xavier, Carbonnel, Franck, Vaysse, Thibaud, Seksik, Philippe, Beaugerie, Laurent, Cosnes, Jacques, Sokol, Harry, Landman, Cecilia, Bourrier, Anne, Nancey, Stephane, Boschetti, Gilles, Laharie, David, Poullenot, Florian, Allez, Matthieu, Gornet, Jean‐Marc, Baudry, Clautilde, Savoye, Guillaume, Moreau, Jacques, Vuitton, Lucine, Koch, Stephane, Viennot, Stephanie, Aubourg, Alexandre, Picon, Laurence, Pelletier, Anne‐Laure, Sickersen, Gaelle, Bouguen, Guillaume, Abitbol, Vered, Chaussade, Stanislas, Fumery, Mathurin, Nahon, Stephane, Winkfield, Betsy, Brixi‐benmansour, Hedia, Gincul, Rodica, Barberis, Jean‐Christophe, Bonaz, Bruno, Michiels, Christophe, Zerbib, Franck, Bourrier de Beauregard, Marie, Locher, Christophe, Davin‐Couve, Sophie, Poirette, Armelle, Guillem, Laurence, Stetiu‐Mocanu, Monica, Philippe, Beau, Beorchia, Sylvain, and Al Qaddi, Jawad

Published
2018
Full Text
View/download PDF

24. How to manage inflammatory bowel disease patients when they withdraw anti-TNF due to severe anti-TNF-induced skin lesions? A multicenter cohort study

Author

Cottron, C, Treton, X, Altwegg, R, Reenaers, C, Amiot, A, Fumery, Mathurin, Vuitton, L, Peyrin-Biroulet, L, Bouguen, G, Dewit, O, Nancey, S, Caillo, L, Roblin, X, Beylot-Barry, M, Rivière, P, Laharie, D, CHU Bordeaux [Bordeaux], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Liège (CHU-Liège), CHU Henri Mondor [Créteil], Chirurgie digestive [CHU Amiens], CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université Catholique de Louvain = Catholic University of Louvain (UCL), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), and Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)

Subjects
inflammatory bowel disease, [SDV]Life Sciences [q-bio], skin lesions, anti-TNF
Abstract

International audience; Background and aims - Optimal management of patients with inflammatory bowel disease [IBD] after anti-tumour necrosis factor [TNF] discontinuation due to severe induced skin lesions is unclear. Our study aimed to describe dermatological and IBD evolution after anti-TNF discontinuation for this side effect. Methods - We conducted a multicentre retrospective study including consecutive IBD patients who discontinued anti-TNF due to severe induced skin lesions. Our objectives were to determine factors associated with dermatological remission [complete disappearance of skin lesions] and with IBD relapse in patients with inactive disease at inclusion, notably the impact of an early switch to another biological agent within 3 months of anti-TNF discontinuation. Results - Among the 181 patients [134 women, 160 Crohn's disease] included in the 13 participating centres, dermatological remission occurred in 110 [62%] patients with a median [interquartile range, IQR] interval of 8.0 [6.8-11.0] months. Scalp location was independently associated with less remission of skin lesions (hazard ratio [HR] = 0.64 [95% CI 0.43-0.94], p = 0.02) while early switch was independently associated with a higher probability of remission of skin lesions (HR = 1.64 [95% CI 1.1-2.5], p = 0.02). Among the 148 patients with inactive IBD at inclusion, disease relapse occurred in 75 [51%] patients with a median [IQR] interval of 26.0 [23.0-39.1] months. Survival rates without IBD relapse at 1 year were 85.8% [95% CI 77.5-94.9] in the early switch group and 59.3% [95% CI 48.9-71.9] in the other group [p

Published
2022
Full Text
View/download PDF

25. Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study

Author

Cottron, C., Treton, X., Altwegg, R., Reenaers, C., Amiot, A., Fumery, Mathurin, Vuitton, L., Peyrin-Biroulet, L., Bouguen, G., Dewit, O., Nancey, S., Caillo, L., Roblin, X., Beylot-Barry, M., Riviere, P., Laharie, D., CHU Bordeaux [Bordeaux], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Liège (CHU-Liège), CHI Créteil, CHU Amiens-Picardie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Universitaire de Nancy (CHU Nancy), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Pontchaillou [Rennes], Université Catholique de Louvain = Catholic University of Louvain (UCL), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), and Jonchère, Laurent

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2022
Full Text
View/download PDF

26. Recommandations de pratique pour le diagnostic et la prise en charge de la rectocolite hémorragique

Author

Amiot, A., Viennot, S., Uzzan, M., Riviere, P., Cosquer, G.L., Yzet, C., Biron, A, Gilletta, C., Abitbol, V., Vuitton, L., Nachury, M., Simon, M., Remy, A.-J., Nahon, S., Faure, P., Guillo, L., Wils, P., Brixi, H., Bourrier, A., Serrero, M., Caillo, L., Bouguen, G., Laharie, D, Hôpital Bicêtre, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Henri Mondor, CHU Bordeaux [Bordeaux], CHU Amiens-Picardie, Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Mutualiste de Montsouris (IMM), Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Clinique Ambroise Paré [Centres Médico-Chirurgicaux Ambroise Pré, Pierre Cherest, Hartmann], CHU Marseille, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and CHU Pontchaillou [Rennes]

Subjects
[SDV]Life Sciences [q-bio], Inflammatory Bowel Disease, diagnostic, guidelines, ulcerative colites, traitement
Abstract

National audience; Background: Updating French clinical guidelines for diagnostic and management of ulcerative colitis is needed due to the emergence of new treatments and treatment goals. Methods: On behalf of the Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID), French clinical guidelines were updated through a validated process of adaptation of clinical guidelines from international Gastroenterology societies and French consensus meetings. Results: French clinical guidelines for the diagnostic and management of ulcerative colitis were drafted by 16 GETAID members and reviewed by 6 members of the GETAID, the Association Nationale des Hépato-gastroentérologues des Hôpitaux généraux (ANGH) and the Club de Réflexion des Cabinets et Groupes d'Hépato-Gastroentérologie (CREGG), graded according to the level of Evidence and the level of agreement by 68 experts from the latter three societies. The present guidelines focused on classification, diagnosis, histopathology, extra-intestinal manifestations, dysplasia and colorectal cancer, pouchitis, medical management of active disease and maintenance therapy.. Conclusion: This paper provides updated and useful guidelines for French gastroenterologists to diagnose and treat patients with ulcerative colitis. © John Libbey Eurotext, 2022.

Published
2022
Full Text
View/download PDF

27. Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent

Author

Buisson, A., Nachury, M., Fumery, Mathurin, Guilmoteau, T., Leclerc, E., Altwegg, R., Serrero, M., Mathieu, N., Treton, X., Vuitton, L., Pereira, B., Amiot, A., Bouguen, G., CHU Clermont-Ferrand, Hôpital Claude Huriez [Lille], CHU Lille, CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Institut de recherches sur la catalyse et l'environnement de Lyon (IRCELYON), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Henri Mondor [Créteil], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and CHU Pontchaillou [Rennes]

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2022

28. Switch from intravenous to subcutaneous infliximab in inflammatory bowel disease: Which consequences from a pharmacokinetic perspective?

Author

Franck, B., Verdier, M.C., Bellissant, E., Bouguen, G., Lemaitre, F., Tron, C., CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Service de Pharmacologie [Rennes]

Subjects
exposure, inflammatory bowel disease, therapeutic drug monitoring, [SDV]Life Sciences [q-bio], sub-cutaneous, infliximab
Abstract

International audience; Meeting Abstract CO-060

Published
2022

29. How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study

Author

Cottron, C, primary, Treton, X, additional, Altwegg, R, additional, Reenaers, C, additional, Amiot, A, additional, Fumery, M, additional, Vuitton, L, additional, Peyrin-Biroulet, L, additional, Bouguen, G, additional, Dewit, O, additional, Nancey, S, additional, Caillo, L, additional, Roblin, X, additional, Beylot-Barry, M, additional, Rivière, P, additional, and Laharie, D, additional

Published
2022
Full Text
View/download PDF

30. DOP76 Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent

Author

Buisson, A, primary, Nachury, M, additional, Fumery, M, additional, Guilmoteau, T, additional, Leclerc, E, additional, Altwegg, R, additional, Serrero, M, additional, Mathieu, N, additional, Treton, X, additional, Vuitton, L, additional, Pereira, B, additional, Amiot, A, additional, and Bouguen, G, additional

Published
2022
Full Text
View/download PDF

31. DOP36 Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter study

Author

Sallette, M, primary, Bouhnik, Y, additional, Nachury, M, additional, Bellanger, C, additional, Laharie, D, additional, Amiot, A, additional, Peyrin-Biroulet, L, additional, Roblin, X, additional, Altwegg, R, additional, Buisson, A, additional, Reenaers, C, additional, Bouguen, G, additional, Vuitton, L, additional, Bourreille, A, additional, Gilletta, C, additional, Serrero, M, additional, Hébuterne, X, additional, and Filippi, J, additional

Published
2022
Full Text
View/download PDF

32. P207 COVID-19: a prevalence rate two times lower than that of the general population in French patients with Inflammatory Bowel Disease treated with intravenous biologic agents

Author

Lelong, M, primary, Nancey, S, additional, Bouguen, G, additional, Allez, M, additional, Serrero, M, additional, Chupin, A, additional, Caillo, L, additional, Viennot, S, additional, Blanc, P, additional, Reimund, J M, additional, Laharie, D, additional, Olivier, R, additional, Laurent, P B, additional, Dib, N, additional, De Maissin, A, additional, Montuclard, C, additional, Trang-Poisson, C, additional, Gaillot, G, additional, Bressollette-Bodin, C, additional, Berthome, M, additional, Burel, M, additional, Vavasseur, F, additional, Bourreille, A, additional, and Le Berre, C, additional

Published
2022
Full Text
View/download PDF

33. P558 Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study

Author

Cottron, C, primary, Treton, X, additional, Altwegg, R, additional, Reenaers, C, additional, Amiot, A, additional, Fumery, M, additional, Vuitton, L, additional, Peyrin-Biroulet, L, additional, Bouguen, G, additional, Dewit, O, additional, Nancey, S, additional, Caillo, L, additional, Roblin, X, additional, Beylot-Barry, M, additional, Rivière, P, additional, and Laharie, D, additional

Published
2022
Full Text
View/download PDF

36. COMBIO : efficacité et tolérance des associations de thérapies ciblées chez les patients atteints de maladies inflammatoires à médiation immunitaire

Author

Flachaire, B., primary, Guillo, L., additional, Avouac, J., additional, Nachury, M., additional, Carbonnel, F., additional, Bouguen, G., additional, Buisson, A., additional, Caillo, L., additional, Fumery, M., additional, Gilleta, C., additional, Hebuterne, X., additional, Lafforgue, P., additional, Laharie, D., additional, Mahé, E., additional, Marotte, H., additional, Nancey, S., additional, Ottaviani, S., additional, Salmon, J.H., additional, Guillaume, S., additional, Serrero, M., additional, Uzzan, M., additional, Viguier, M.A., additional, Richez, C., additional, Peyrin-Biroulet, L., additional, Seksik, P., additional, and Pham, T., additional

Published
2021
Full Text
View/download PDF

38. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with real-world ulcerative colitis: A GETAID multicentre cohort study

Author

Fumery, Mathurin, Filippi, J., Abitbol, V., Biron, A., Laharie, D., Serrero, M., Altwegg, R., Bouhnik, Y., Peyrinbiroulet, L., Gilletta, C., Roblin, X., Chambrun, G. Pineton, Vuitton, L., Bourrier, A., Nancey, S., Gornet, J. M., Nahon, S., Bouguen, G., Viennot, S., Pariente, B., Amiot, A., Service d'Hépato Gastroenterologie [CHU Amiens-Picardie], CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Clichy, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital Pasteur [Nice] (CHU), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Hôpital Claude Huriez [Lille], CHU Lille, and CHU Henri Mondor [Créteil]

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience; Background: Phase III trials have demonstrated the efficacy and safety of ustekinumab in moderate-to-severe ulcerative colitis (UC), but no real-life long-term data is currently available. Methods: From January to September 2019, all consecutive patients with active UC treated with ustekinumab in a GETAID centre were included. Patients were evaluated at week 52. Remission was defined by a partial Mayo Clinic score ≤ 2. The aim of the present study was to assess long-term effectiveness and safety of usteki numab in UC. Results: 103 UC patients (62 men; mean age: 41.2 ± 16.2 years; 52% pancolitis E3) were included in 21 centres. History of immunomodulator, anti-TNF and vedolizumab therapies was noted in 84.5%, 99.0% and 85.4% of the cases, respectively. At week 54, 44 (43%) patients discontinued ustekinumab, for lack of efficacy (n=41), pregnancy (n=1), persistence of eczematiform lesions (n=1) or personal decision (n=1). Cumulative probabilities of ustekinumab persistence were 96.1%, 81.6%, 71.7%, and 58.4% after 3, 6, 9, and 12 months, respectively. In multivariate analysis, a CRP>5 mg/L at week 0 (OR=2.91, CI95%[1.15–7.36]; p=0.02) and concomitant steroids at week 0 (OR=3.05, CI95%[1.30–7.14]; p=0.01) were significantly associated with ustekinumab discontinuation within one year. The overall rate of steroid-free clinical remission at week 52 was 32% of whom 71% had null rectal bleeding and stool frequency Downloaded from https://academic.oup.com/ecco-jcc/article/15/Supplement_1/S486/6286779 by guest on 03 February 2022 Abstracts of the 16th Congress of ECCO - European Crohn's and Colitis Organisation S487 subscores. Ten patients (9.7%) underwent colectomy within a median of 6.7 [4.3–10.6] months. Adverse events were observed in 15 (16.9%) patients, of whom 4 (4.5%) had severe adverse events including three patients with exacerbation of UC leading to hospitalization, and a 62 years-old men who died from a myocardial infarction four months after ustekinumab initiation. Conclusion: In this real-world cohort study that included patients with refractory ulcerative colitis to multiple therapies, more than one-half of patients were still treated by ustekinumab and one-third were in steroid-free clinical remission, after 52 weeks.

Published
2021
Full Text
View/download PDF

39. Management of perianal fistulas in Crohn's disease: a 2021 update of the French National Society of Coloproctology consensus.

Author

Bouchard, D., Pigot, F., de Parades, V., Staumont, G., Abramowitz, L., Siproudhis, L., Members of the SNFCP, Tracanelli, L., Fathallah, N., Babin-Pigot, E., Ferry, M., Members of the GETAID, Bouguen, G., Laharie, D., Cotte, E., Panis, Y., Peyrin-Biroulet, L., Roblin, X., and Zerbib, P.

Subjects
CROHN'S disease, ANAL diseases, TUMOR necrosis factors, MAGNETIC resonance imaging, FISTULA, STEM cells
Abstract

Background: Since our last publication of algorithms for the management of perianal fistulas in patients with Crohn's disease, researchers have proposed a treat to target strategy systematic combotherapy for anal lesions, and indications for stem cell injection. In the absence robust publications, the Société Nationale Française de Coloproctologie (French National Society of Coloproctology [SNFCP]) wished to establish a group consensus using the Delphi method. Methods: From October 2020 to January 2021, a scientific committee and panel of gastroenterologists and surgeons established answers which were submitted to the members of the SNFCP during a national conference in November 2020. Three questions were clarified and reformulated, and then submitted during a third and final round of consultation of members of the SNFCP. Results: The target was defined as being the response obtained in every domain (symptoms, physical and radiological evaluation) which could be considered satisfactory, without the need to intensify therapeutic management. By consensus, the time required for clinical evaluation of the efficacy of treatment was 6 months. A response on magnetic resonance imaging (MRI) should include the absence of a collection of 10 mm or more in size at 6 months, and a frank decrease or complete disappearance of hyperintensity in T1 and T2 sequences of the main tract at 12 months. Systematic association of an immunosuppressant with tumor necrosis factor inhibitors did not reach the consensus level for adalimumab (50%), but just did for infliximab (70%). The majority of the respondents considered failure of one, or even two lines of different biotherapies to be potential indications for injection of stem cells. Conclusions: These findings reinforce the importance of composite targets including MRI evaluation, and underscore the need for precise timing of evaluation. Combotherapy is only recommended with infliximab. Injection of stem cells is a second- or third-line option. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

40. Management of inflammatory bowel disease: Update 2021

Author

Amiot, A., Bouguen, G., Bonnaud, G., Bouhnik, Y., Hagège, H., Peyrin-Biroulet, L., CHU Henri Mondor [Créteil], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Ambroise Paré [AP-HP], CHU Clichy, CHI Créteil, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Henri Mondor, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), and CRHU Nancy

Subjects
[SDV]Life Sciences [q-bio]
Abstract

National audience; Background: The treatment of inflammatory bowel diseases is constantly evolving through the emergence of novel molecules and treatment goals. Implementing those progresses in daily clinical practice is necessary. Methods: Thirty-one gastroenterologists practicing in France were invited to participate in a one-day consensus meeting to update previous algorithms on management of patients with Crohn's disease and ulcerative colitis for various situations. Consensus was defined as at least 66% of experts agreeing on a response. Results: All the algorithms were previously designed assuming that patients experienced a first flare of inflammatory bowel disease and are naïve of any treatment. The consensus meeting permitted to update the previous consensus algorithms through 13 clinical situations for first, second and third-line treatment of patients with Crohn's disease and ulcerative colitis. Conclusion: The changes incorporated to the algorithms provide useful guidelines to treat patients with inflammatory bowel diseases including new molecules such as vedolizumab, ustékinumab and tofacitinib and new treatment strategies. © 2021 John Libbey Eurotext. All rights reserved.

Published
2021
Full Text
View/download PDF

43. P321 Cessation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn’s Disease: Individual Patient Data Meta-Analysis of 323 patients from 12 studies

Author

Ten Bokkel Huinink, S, primary, van der Woude, J, additional, Casanova, M J, additional, Bouguen, G, additional, Mak, J W Y, additional, Molnar, T, additional, Seidelin, J, additional, Aurelien, A, additional, D’Haens, G, additional, Riviere, P, additional, Guidi, L, additional, Renata, B, additional, Lin, W C, additional, and de Vries, A, additional

Published
2021
Full Text
View/download PDF

44. P504 Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with real-world ulcerative colitis: A GETAID multicentre cohort study

Author

Fumery, M, primary, Filippi, J, additional, Abitbol, V, additional, Biron, A, additional, Laharie, D, additional, Serrero, M, additional, Altwegg, R, additional, Bouhnik, Y, additional, Peyrinbiroulet, L, additional, Gilletta, C, additional, Roblin, X, additional, Pineton de Chambrun, G, additional, Vuitton, L, additional, Bourrier, A, additional, Nancey, S, additional, Gornet, J M, additional, Nahon, S, additional, Bouguen, G, additional, Viennot, S, additional, Pariente, B, additional, and Amiot, A, additional

Published
2021
Full Text
View/download PDF

45. Validation of IBD-disk for the assessment of daily-life burden of patients with inflammatory bowel disease

Author

Tadbiri, S., Nachury, M., Bouhnik, Y., Serrero, M., Jerome, F., Roblin, X., Bourrier, A., Bouguen, G., Franchimont, D., Savoye, G., Buisson, A., Louis, E., Nancey, S., Abtibol, V., Reimund, J. M., Dewitt, O., Vuitton, L., Matthieu, N., Peyrin-Biroulet, L., Gilletta, C., Allez, M., Viennot, S., Bourreille, A., Dib, N., Brixi, H., Boualit, M., Plastaras, L., Altwegg, R., Fumery, Mathurin, Caillo, L., Laharie, D., Amiot, A., Hôpital Claude Huriez [Lille], CHU Lille, Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'Hépato-gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Pontchaillou [Rennes], Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Clermont-Ferrand, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut des Maladies de l'Appareil Digestif, Université de Nantes (UN), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre hospitalier [Valenciennes, Nord], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375) (EC2M3), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

46. No severe neonatal and maternal complications in inflammatory bowel diseases patients treated with ustekinumab or vedolizumab during pregnancy

Author

Wils, P., Seksik, P., Stefanescu, C., Nancey, S., Allez, M., Laharie, D., de Chambrun, G. Pineton, Altwegg, R., Gilletta, C., Vuitton, L., Viennot, S., Serrero, M., Fumery, Mathurin, Savoye, G., Collins, M., Goutorbe, F., Brixi, H., Bouguen, G., Tavernier, N., Boualit, M., Amiot, A., Abitbol, V., Pariente, B., Grp, Getaid, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Beaujon, Assistance Publique - Hôpitaux de Paris, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Department of Physics, University of Surrey, University of Surrey (UNIS), Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre Hospitalier de la Côte Basque, CHU Pontchaillou [Rennes], Centre for Systems Biology, Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada, Programme équipe Labellisée Ligue Contre le Cancer, Institut Jacques Monod, UMR7592, Université de Paris, CNRS, Paris, France, Centre hospitalier [Valenciennes, Nord], Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375) (EC2M3), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Claude Huriez [Lille], CHU Lille, and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

48. Effectiveness and safety of ustekinumab induction therapy in ulcerative colitis: A GETAID real-world cohort study

Author

Amiot, A., Vered, A., Filippi, J., Cadiot, G., Laharie, D., Melanie, S., Altwegg, R., Bouhnik, Y., Peyrin-Biroulet, L., Gilletta, C., Roblin, X., Chambrun, G. Pineton, Vuitton, L., Bourrier, A., Nancey, S., Gornet, J. M., Nahon, S., Bouguen, G., Viennot, S., Benjamin, P., Fumery, Mathurin, DESSAIVRE, Louise, Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375) (EC2M3), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Universitaire de Nice (CHU Nice), Centre Hospitalier Universitaire de Reims (CHU Reims), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service d'Hépato-gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Hôpital Pasteur [Nice] (CHU), CHU Pontchaillou [Rennes], CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), and Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

49. Acceptability of treatment regimen in inflammatory bowel disease: Results from a prospective nationwide study (ACCEPT2)

Author

Buisson, A., Fumery, Mathurin, Serrero, M., Orsat, L., Nancey, S., Riviere, P., Altwegg, R., Peyrin-Biroulet, L., Nachury, M., Hebuterne, X., Gilletta, C., Flamant, M., Viennot, S., Bouguen, G., Amiot, A., Mathieu, S., Vuitton, L., Plastaras, L., Bourreille, A., Caillo, L., Goutorbe, F., Chambrun, G. Pineton, Attar, A., Roblin, X., Pereira, B., Pariente, B., and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio]
Published
2020

Catalog

Books, media, physical & digital resources
See catalog results